133 related articles for article (PubMed ID: 2793372)
1. Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity.
Abbruzzese JL; Schmidt S; Raber MN; Levy JK; Castellanos AM; Legha SS; Krakoff IH
Invest New Drugs; 1989 Jul; 7(2-3):195-201. PubMed ID: 2793372
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU).
Fanucchi MP; Leyland-Jones B; Young CW; Burchenal JH; Watanabe KA; Fox JJ
Cancer Treat Rep; 1985 Jan; 69(1):55-9. PubMed ID: 2981621
[TBL] [Abstract][Full Text] [Related]
3. Nucleosides. 146. 1-Methyl-5-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil, the C-nucleoside isostere of the potent antiviral agent 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)thymine (FMAU). Studies directed toward the synthesis of 2'-deoxy-2'-substituted arabino nucleosides. 6.
Pankiewicz KW; Nawrot B; Gadler H; Price RW; Watanabe KA
J Med Chem; 1987 Dec; 30(12):2314-6. PubMed ID: 2824777
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats.
Wright JD; Ma T; Chu CK; Boudinot FD
Pharm Res; 1995 Sep; 12(9):1350-3. PubMed ID: 8570534
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
Brown TD; Ettinger DS; Donehower RC
J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
[TBL] [Abstract][Full Text] [Related]
6. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.
Warrell RP; Berman E
J Clin Oncol; 1986 Jan; 4(1):74-9. PubMed ID: 2416889
[TBL] [Abstract][Full Text] [Related]
7. 1-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil. A highly selective antiherpes simplex agent.
Mansuri MM; Ghazzouli I; Chen MS; Howell HG; Brodfuehrer PR; Benigni DA; Martin JC
J Med Chem; 1987 May; 30(5):867-71. PubMed ID: 3033244
[TBL] [Abstract][Full Text] [Related]
8. Journey of 2'-deoxy-2'-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU): from Antiviral Drug to PET Imaging Agent.
Alauddin MM
Curr Med Chem; 2018; 25(16):1867-1878. PubMed ID: 29189119
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of oxaliplatin in patients with advanced cancer.
Extra JM; Espie M; Calvo F; Ferme C; Mignot L; Marty M
Cancer Chemother Pharmacol; 1990; 25(4):299-303. PubMed ID: 2295116
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical evaluation of doxifluridine.
Hurteloup P; Armand JP; Cappelaere P; Metz R; Kerbrat P; Keiling R; Fumoleau P; Fargeot P; Schraub S; Bastit P
Cancer Treat Rep; 1986 Jun; 70(6):731-7. PubMed ID: 2942245
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule.
Cobb PW; Havlin KA; Kuhn JG; Craig JB; Harman GS; Luther JS; Turner JN; Weiss GR; Tweedy DA; Koeller J
Sel Cancer Ther; 1991; 7(2):85-91. PubMed ID: 1754731
[TBL] [Abstract][Full Text] [Related]
12. Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
Eiseman JL; Brown-Proctor C; Kinahan PE; Collins JM; Anderson LW; Joseph E; Hamburger DR; Pan SS; Mathis CA; Egorin MJ; Klecker RW
Clin Cancer Res; 2004 Oct; 10(19):6669-76. PubMed ID: 15475457
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of diaziquone in patients with colon cancer.
Neidhart JA; Erlichman C; Robert F; Velez-Garcia E; Bender JF; Grillo-López J
Cancer Treat Rep; 1985 Feb; 69(2):215-7. PubMed ID: 3882229
[TBL] [Abstract][Full Text] [Related]
14. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
15. Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil.
Matulic-Adamic J; Takahashi K; Chou TC; Gadler H; Price RW; Reddy AR; Kalman TI; Watanabe KA
J Med Chem; 1988 Aug; 31(8):1642-7. PubMed ID: 2840503
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of spirogermanium given daily.
Legha SS; Ajani JA; Bodey GP
J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity.
Wang J; Eriksson S
Antimicrob Agents Chemother; 1996 Jun; 40(6):1555-7. PubMed ID: 8726039
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
